α4β7 integrin-dependent adhesion of T cells to MAdCAM-1 is blocked by vedolizumab in patients with chronic refractory pouchitis

Background: The anti-α4β7 integrin antibody vedolizumab is an established therapeutic option for the treatment of inflammatory bowel disease (IBD). It has also been successfully used in patients with chronic antibiotic-refractory pouchitis following proctocolectomey with ileal pouch-anal anastomosis...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Michaela Melde, Tanja M. Müller, Ines Schneider, Carol-Immanuel Geppert, Laura Mühl, Laura Besendorf, Clarissa Allner, Emily Becker, Imke Atreya, Francesco Vitali, Raja Atreya, Markus F. Neurath, Sebastian Zundler
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	SAGE Publishing 2021-11-01
Edice:	Therapeutic Advances in Gastroenterology
On-line přístup:	https://doi.org/10.1177/17562848211054707
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!